Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts*

Proteolytic degradation of extracellular matrix (ECM) components during tissue remodeling plays a pivotal role in normal and pathological processes including wound healing, inflammation, tumor invasion, and metastasis. Proteolytic enzymes in tumors may activate or release growth factors from the ECM or act directly on the ECM itself, thereby facilitating angiogenesis or tumor cell migration. Fibroblast activation protein (FAP) is a cell surface antigen of reactive tumor stromal fibroblasts found in epithelial cancers and in granulation tissue during wound healing. It is absent from most normal adult human tissues. FAP is conserved throughout chordate evolution, with homologues in mouse and Xenopus laevis, whose expression correlates with tissue remodeling events. Using recombinant and purified natural FAP, we show that FAP has both dipeptidyl peptidase activity and a collagenolytic activity capable of degrading gelatin and type I collagen; by sequence, FAP belongs to the serine protease family rather than the matrix metalloprotease family. Mutation of the putative catalytic serine residue of FAP to alanine abolishes both enzymatic activities. Consistent with its in vivo expression pattern determined by immunohistochemistry, FAP enzyme activity was detected by an immunocapture assay in human cancerous tissues but not in matched normal tissues. This study demonstrates that FAP is present as an active cell surface-bound collagenase in epithelial tumor stroma and opens up investigation into physiological substrates of its novel, tumor-associated dipeptidyl peptidase activity.

[1]  W. Li,et al.  Up‐regulation of tissue inhibitor of metalloproteinases‐3 gene expression by TGF‐β in articular chondrocytes is mediated by serine/threonine and tyrosine kinases , 1998, Journal of cellular biochemistry.

[2]  A. Newby,et al.  Synergistic upregulation of metalloproteinase‐9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF‐κB , 1998, FEBS letters.

[3]  W. Reutter,et al.  Rat dipeptidyl peptidase IV (DPP IV) exhibits endopeptidase activity with specificity for denatured fibrillar collagens , 1998, FEBS letters.

[4]  Dominique Schols,et al.  Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV , 1998, The Journal of Biological Chemistry.

[5]  M. Ditto,et al.  Regulation of the Receptor Specificity and Function of the Chemokine RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) by Dipeptidyl Peptidase IV (CD26)-mediated Cleavage , 1997, The Journal of experimental medicine.

[6]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[7]  P. McCann,et al.  Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. , 1997, Pharmacology & therapeutics.

[8]  A. Schnapp,et al.  Mouse fibroblast activation protein: Molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers , 1997, International journal of cancer.

[9]  Jackson Rc,et al.  Contributions of protein structure-based drug design to cancer chemotherapy. , 1997 .

[10]  J. Dodt,et al.  Identification of the 170-kDa Melanoma Membrane-bound Gelatinase (Seprase) as a Serine Integral Membrane Protease* , 1997, The Journal of Biological Chemistry.

[11]  H. Mittrücker,et al.  The T-cell receptor associated zeta-chain is required but not sufficient for CD26 (dipeptidylpeptidase IV) mediated signaling. , 1997, Immunology letters.

[12]  B. Davidson,et al.  Inflammatory Response in Cervicallntraepithelial Neoplasia and Squamous Cell Carcinoma of the Uterine Cervix , 1997 .

[13]  L. Liotta,et al.  Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. , 1996, The American journal of pathology.

[14]  Y. Okada,et al.  MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. , 1996, Journal of cell science.

[15]  Z. Wang,et al.  The thyroid hormone-induced tail resorption program during Xenopus laevis metamorphosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Fridman,et al.  Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). , 1995, Cancer research.

[17]  Stephen J. Weiss,et al.  Furin-dependent intracellular activation of the human stromelysin-3 zymogen , 1995, Nature.

[18]  A. Kehlen,et al.  Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell‐derived cytokines, such as IL‐4 and IL‐13 , 1995, Clinical and experimental immunology.

[19]  E. Kohn,et al.  Molecular insights into cancer invasion: strategies for prevention and intervention. , 1995, Cancer research.

[20]  R. Chaganti,et al.  The gene for fibroblast activation protein alpha (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. , 1995, Genomics.

[21]  W. T. Chen,et al.  A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. , 1994, Cancer research.

[22]  J. Winer,et al.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.

[23]  N. Brünner,et al.  Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. , 1994, Cancer research.

[24]  J. Healey,et al.  Fibroblast activation protein: Purification, epitope mapping and induction by growth factors , 1994, International journal of cancer.

[25]  J. Healey,et al.  Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  W. Stetler-Stevenson,et al.  Quantitative zymography: detection of picogram quantities of gelatinases. , 1994, Analytical biochemistry.

[27]  M. Schutkowski,et al.  Influence on proline-specific enzymes of a substrate containing the thioxoaminoacyl-prolyl peptide bond. , 1994, European journal of biochemistry.

[28]  B. Fleischer,et al.  CD26: a surface protease involved in T-cell activation. , 1994, Immunology today.

[29]  A. Turner,et al.  Post-secretory processing of regulatory peptides: the pancreatic polypeptide family as a model example. , 1994, Biochimie.

[30]  L. Liotta,et al.  Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  J. Healey,et al.  Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. , 1993, Cancer research.

[32]  R. Wenthold,et al.  Non-conservation of a catalytic residue in a dipeptidyl aminopeptidase IV-related protein encoded by a gene on human chromosome 7. , 1993, Human molecular genetics.

[33]  A. Lanzavecchia,et al.  Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation , 1993, The Journal of experimental medicine.

[34]  L. Liotta,et al.  Expression of human recombinant 72 kDa gelatinase and tissue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme. , 1993, The Biochemical journal.

[35]  L. Liotta,et al.  Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. , 1992, Human pathology.

[36]  B. Seed,et al.  Cloning and functional expression of the T cell activation antigen CD26. , 1992, Journal of immunology.

[37]  H. de Smedt,et al.  Differences in regulation between nuclear and cytoplasmic Ca2+ in cultured smooth muscle cells. , 1992, The American journal of physiology.

[38]  A. Mountain,et al.  Engineering antibodies for therapy. , 1992, Biotechnology & genetic engineering reviews.

[39]  R. Wenthold,et al.  Differential expression of two distinct forms of mRNA encoding members of a dipeptidyl aminopeptidase family. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. O'reilly,et al.  Baculovirus expression vectors: a laboratory manual. , 1992 .

[41]  J. Gorvel,et al.  Expression of sucrase-isomaltase and dipeptidylpeptidase IV in human small intestine and colon. , 1991, Gastroenterology.

[42]  J. E. Park,et al.  Biosynthesis of lysosomal enzymes in cells of the End3 complementation group conditionally defective in endosomal acidification , 1991, Somatic cell and molecular genetics.

[43]  L. Old,et al.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Melamed,et al.  Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[45]  P. Horan,et al.  Flow cytometry in the clinical laboratory. , 1988, Clinica chimica acta; international journal of clinical chemistry.

[46]  T. Nagatsu,et al.  A sensitive and specific assay for dipeptidyl-aminopeptidase II in serum and tissues by liquid chromatography-fluorometry. , 1985, Analytical Biochemistry.

[47]  R. Manteuffel,et al.  Fluorographic detection of tritium-labelled proteins in immunoelectropherograms with the water-soluble fluor, sodium salicylate. , 1983, Journal of biochemical and biophysical methods.

[48]  D. Steiner,et al.  Conversion of proinsulin to insulin: involvement of a 31,500 molecular weight thiol protease. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[49]  S. Gordon,et al.  A factor X-activating cysteine protease from malignant tissue. , 1981, The Journal of clinical investigation.

[50]  M. Mihm,et al.  Melanoma. An ultrastructural study of the host inflammatory and vascular responses. , 1980, The Journal of investigative dermatology.

[51]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[52]  S. Yun,et al.  A simple method for calculating Km and V from a single enzyme reaction progress curve. , 1977, Biochimica et biophysica acta.

[53]  R. Hayashi,et al.  Further confirmation of carboxypeptidase Y as a metal-free enzyme having a reactive serine residue. , 1975, Journal of biochemistry.

[54]  Y. Hayashi,et al.  Protein and RNA synthesis in the skeletal muscle of hereditary dystrophic mouse. , 1975, Journal of biochemistry.

[55]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[56]  L. Engström,et al.  Studies on Streptomyces griseus protease. II. The amino acid sequence around the reactive serine residue of DFP-sensitive components with esterase activity. , 1968, Biochimica et biophysica acta.